Home › Companies › RELAY THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and RELAY THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 6, 2025: 4 items on RELAY THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025: 2 elected · 2 approved.
Significant dissent: 2 directors (35.7%, 34.8% against); 1 say-on-pay vote (56.4% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore RELAY THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are RELAY THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Alexis Borisy | 80,716,409 | -- | -- | 43,000,380 | 18,744,478 | 65% | Elected | — |
| Elect Director: Mark Murcko, Ph.D. | 79,505,170 | -- | -- | 44,211,619 | 18,744,478 | 64% | Elected | — |
| 2. Non-binding advisory vote on executive compensation | 69,745,321 | 53,852,178 | 119,290 | -- | 18,744,478 | 56% | Approved | — |
| 3. Ratification of appointment of independent registered public accounting firm | 142,184,207 | 163,544 | 113,516 | -- | -- | 99.9% | Approved | — |
Source: RELAY THERAPEUTICS INC., Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
178 asset managers disclosed a vote on at least one RELAY THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
65% Majority: yes · of votes cast
Description as filed by funds: To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Alexis Borisy
RELAY THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alexis Borisy”): 80,716,409 for, 43,000,380 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company's 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignati…”
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 26,592,394 for, 10,036,673 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,929,791 | 0 | 0 | 0 | For |
| BlackRock | 3,897,788 | 0 | 0 | 0 | For |
| JPMorgan | 3,053,700 | 0 | 0 | 0 | For |
| Fidelity | 2,868,478 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 0 | 0 | 0 | 2,682,083 | Withhold |
| State Street | 5,958 | 0 | 0 | 2,485,355 | Withhold |
| T. Rowe Price | 2,375,989 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1,520,316 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 1,066,050 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 592,807 | Withhold |
| Columbia Threadneedle | 365,223 | 0 | 0 | 0 | For |
| Equitable | 218,828 | 0 | 0 | 136,181 | Mixed |
| American Century | 0 | 0 | 0 | 312,790 | Withhold |
| TIAA | 294,765 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 247,180 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 209,651 | 0 | 0 | 0 | For |
| Lincoln Financial | 9,804 | 0 | 0 | 160,894 | Mixed |
| Thrivent | 0 | 0 | 0 | 162,388 | Withhold |
| Prudential/PGIM | 130,100 | 0 | 0 | 20,080 | Mixed |
| Jackson National | 120,026 | 0 | 0 | 23,396 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 139,917 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 118,964 | Withhold |
| Brighthouse | 69,286 | 0 | 0 | 43,536 | Mixed |
| Invesco | 99,184 | 0 | 0 | 0 | For |
| Federated Hermes | 96,570 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Mark Murcko, Ph.D.
RELAY THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mark Murcko, Ph.D.”): 79,505,170 for, 44,211,619 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company's 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignati…”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 25,811,160 for, 10,817,907 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,929,791 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 3,897,788 | Withhold |
| JPMorgan | 3,053,700 | 0 | 0 | 0 | For |
| Fidelity | 2,720,199 | 0 | 0 | 148,279 | Mixed |
| MUTUAL FUND SERIES TRUST | 0 | 0 | 0 | 2,682,083 | Withhold |
| State Street | 2,488,432 | 0 | 0 | 2,881 | For |
| T. Rowe Price | 2,375,989 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1,520,316 | Withhold |
| Charles Schwab | 1,066,050 | 0 | 0 | 0 | For |
| Goldman Sachs | 592,807 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 365,223 | Withhold |
| Equitable | 26,192 | 0 | 0 | 328,817 | Mixed |
| American Century | 0 | 0 | 0 | 312,790 | Withhold |
| TIAA | 294,765 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 247,180 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 209,651 | Withhold |
| Lincoln Financial | 104,204 | 0 | 0 | 66,494 | Mixed |
| Thrivent | 0 | 0 | 0 | 162,388 | Withhold |
| Prudential/PGIM | 130,100 | 0 | 0 | 20,080 | Mixed |
| Jackson National | 120,026 | 0 | 0 | 23,396 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 139,917 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 118,964 | Withhold |
| Brighthouse | 69,286 | 0 | 0 | 43,536 | Mixed |
| Invesco | 0 | 0 | 0 | 99,184 | Withhold |
| Federated Hermes | 96,570 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
56% Approved · of votes cast
Prior year: 59.9% for (June 3, 2024 meeting) ▼ 3.5 pts
Description as filed by funds: To consider and act upon an advisory vote on the compensation of our named executive officers;
RELAY THERAPEUTICS INC.’s own tally for this item (“2. Non-binding advisory vote on executive compensation”): 69,745,321 for, 53,852,178 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, with the votes cast as follows:”
Support: 56% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 11,929,791 | 0 | 0 | Against |
| BlackRock | 3,897,788 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 3,053,700 | 0 | 0 | Against |
| Fidelity | 2,868,478 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 0 | 2,682,083 | 0 | 0 | Against |
| State Street | 2,485,526 | 5,787 | 0 | 0 | For |
| T. Rowe Price | 2,375,989 | 0 | 0 | 0 | For |
| Dimensional | 0 | 1,520,316 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,066,050 | 0 | 0 | Against |
| Goldman Sachs | 0 | 592,807 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 365,223 | 0 | 0 | Against |
| Equitable | 218,828 | 136,181 | 0 | 0 | Mixed |
| American Century | 0 | 312,790 | 0 | 0 | Against |
| TIAA | 0 | 294,765 | 0 | 0 | Against |
| Exchange Place Advisors Trust | 247,180 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 209,651 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,400 | 76,298 | 0 | 0 | Mixed |
| Thrivent | 0 | 162,388 | 0 | 0 | Against |
| Prudential/PGIM | 130,100 | 20,080 | 0 | 0 | Mixed |
| Jackson National | 120,026 | 23,396 | 0 | 0 | Mixed |
| AIG/SunAmerica | 0 | 139,917 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 118,964 | 0 | 0 | Against |
| Brighthouse | 0 | 112,822 | 0 | 0 | Against |
| Invesco | 0 | 99,184 | 0 | 0 | Against |
| Federated Hermes | 96,570 | 0 | 0 | 0 | For |
Fund voting reports, all 57 managers: 13,286,528 for, 23,309,624 against, 32,915 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 27,904,963 | 0 | 0 | 0 | For |
| Point72 | 0 | 13,329,121 | 0 | 0 | Against |
| Bellevue Group AG | 0 | 7,377,292 | 0 | 0 | Against |
| BlackRock | 6,157,410 | 63,215 | 0 | 0 | For |
| Casdin Capital, LLC | 5,467,195 | 0 | 0 | 0 | For |
| State Street | 4,733,580 | 65,262 | 0 | 0 | For |
| JPMorgan | 0 | 3,951,682 | 0 | 0 | Against |
| T. Rowe Price | 3,391,802 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,063,533 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 1,770,283 | 0 | 0 | 0 | For |
| GV Management Company, L.L.C. | 1,564,173 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,498,763 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 1,227,453 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,066,050 | 0 | 0 | Against |
| Kynam Capital Management, LP | 0 | 0 | 0 | 1,031,265 | Withhold |
| Foresite Capital Management IV, LLC | 1,000,000 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 959,938 | 0 | 0 | Against |
| Renaissance | 0 | 766,641 | 0 | 0 | Against |
| TFG Asset Management GP Ltd | 699,000 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 541,124 | 0 | 0 | 0 | For |
| UBS | 0 | 459,744 | 0 | 0 | Against |
| BESSEMER TRUST CO | 0 | 457,936 | 0 | 0 | Against |
| BESSEMER TRUST Co NATIONAL ASSOCIATION | 0 | 457,936 | 0 | 0 | Against |
| BESSEMER TRUST Co OF FLORIDA | 0 | 457,936 | 0 | 0 | Against |
| Bessemer Trust CO of Delaware, N.A. | 0 | 457,936 | 0 | 0 | Against |
Institutional-manager reports, all 141 managers: 59,768,966 for, 35,590,369 against, 1,031,265 withheld. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (June 3, 2024 meeting) ▼ 0.1 pts
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and
RELAY THERAPEUTICS INC.’s own tally for this item (“3. Ratification of appointment of independent registered public accounting firm”): 142,184,207 for, 163,544 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, with the votes cast as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 36,596,054 for, 98 against, 32,915 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,929,791 | 0 | 0 | 0 | For |
| BlackRock | 3,897,788 | 0 | 0 | 0 | For |
| JPMorgan | 3,053,700 | 0 | 0 | 0 | For |
| Fidelity | 2,868,478 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 2,682,083 | 0 | 0 | 0 | For |
| State Street | 2,491,215 | 98 | 0 | 0 | For |
| T. Rowe Price | 2,375,989 | 0 | 0 | 0 | For |
| Dimensional | 1,520,316 | 0 | 0 | 0 | For |
| Charles Schwab | 1,066,050 | 0 | 0 | 0 | For |
| Goldman Sachs | 592,807 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 365,223 | 0 | 0 | 0 | For |
| Equitable | 355,009 | 0 | 0 | 0 | For |
| American Century | 312,790 | 0 | 0 | 0 | For |
| TIAA | 294,765 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 247,180 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 209,651 | 0 | 0 | 0 | For |
| Lincoln Financial | 170,698 | 0 | 0 | 0 | For |
| Thrivent | 162,388 | 0 | 0 | 0 | For |
| Prudential/PGIM | 150,180 | 0 | 0 | 0 | For |
| Jackson National | 143,422 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 139,917 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 118,964 | 0 | 0 | 0 | For |
| Brighthouse | 112,822 | 0 | 0 | 0 | For |
| Invesco | 99,184 | 0 | 0 | 0 | For |
| Federated Hermes | 96,570 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 170,483,872 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.00% |
| 2 | BlackRock | 2.29% |
| 3 | JPMorgan | 1.79% |
| 4 | Fidelity | 1.68% |
| 5 | MUTUAL FUND SERIES TRUST | 1.57% |
| 6 | State Street | 1.46% |
| 7 | T. Rowe Price | 1.39% |
| 8 | Dimensional | 0.89% |
| 9 | Charles Schwab | 0.63% |
| 10 | Goldman Sachs | 0.35% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 16.37% |
| 2 | Point72 | 7.82% |
| 3 | Bellevue Group AG | 4.33% |
| 4 | BlackRock | 3.65% |
| 5 | Casdin Capital, LLC | 3.21% |
| 6 | State Street | 2.81% |
| 7 | JPMorgan | 2.32% |
| 8 | T. Rowe Price | 1.99% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.80% |
| 10 | MPM BioImpact LLC | 1.04% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Commodore Capital LP | 17,000,000 | 9.97% | Schedule 13G, filed November 14, 2025 |
| BlackRock | 14,478,798 | 8.49% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 12,105,420 | 7.10% | Form 13F, quarter ended March 31, 2025 |
| Point72 | 10,827,067 | 6.35% | Form 13F, quarter ended March 31, 2025 |
| State Street | 5,159,192 | 3.03% | Form 13F, quarter ended March 31, 2025 |
| JPMorgan Chase | 4,909,771 | 2.88% | Form 13F, quarter ended March 31, 2025 |
| T. Rowe Price | 3,477,791 | 2.04% | Form 13F, quarter ended March 31, 2025 |
| Norges Bank | 3,392,625 | 1.99% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 3,070,118 | 1.80% | Form 13F, quarter ended March 31, 2025 |
| Millennium Management | 2,942,875 | 1.73% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 170,483,872 shares outstanding, as reported by RELAY THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At RELAY THERAPEUTICS INC.'s shareholder meeting held June 6, 2025, in the 2024-2025 proxy season, 178 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 984 separate fund positions. On the most widely held item on that ballot — To consider and act upon an advisory vote on the compensation of our named executive officers; — RELAY THERAPEUTICS INC.'s filing reports the proposal as approved, with 56% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RELAY THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RELAY THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
RELAY THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “RELAY THERAPEUTICS (RLAY) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/relay-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.